EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudie

Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial

Guorui Zhao, Yaoyao Sun, Yuyanan Zhang, Tianlan Lu, Zhe Lu, Zhewei Kang, Johannes Schneider-Thoma, Wuxiang Xie, Yang Yang, Jing Guo, Yunqing Zhu, Rui Yuan und 12 weitere

American Journal of Psychiatry · 2026-02 · 183 (2) · 112-123

DOI: 10.1176/appi.ajp.20250111 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Psychiatry, 2026-02. Verfasst von Guorui Zhao und 23 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Cli…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Antipsychotic drugs are the mainstay of schizophrenia treatment; yet, controversy persists regarding their relative efficacy and side effects, and guideline recommendations on efficacy differences are particularly vague. The aim of this trial was to compare seven antipsychotics in acutely ill patients with schizophrenia. METHODS: The authors performed a multicenter (32 hospitals), industry-independent, parallel, assessor-blinded, flexible-dosage randomized trial (Schizophrenia in Non-Occidental Participants). Eligible inpatients 18-45 years of age with schizophrenia experiencing acute exacerbation were recruited and randomized to 6 weeks of monotherapy with one of seven antipsychotic drugs: olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, perphenazine, and haloperidol. RESULTS: A total of 3,067 patients were randomized, of whom 82% completed follow-up. The mixed model indicated significant differences in the primary outcome percentage change in Positive and Negative Syndrome Scale (PANSS) score between the antipsychotics. At week 6, olanzapine and risperidone showed a significantly higher percentage change in PANSS score than aripiprazole, ziprasidone, and quetiapine (mean differences: 5.52-7.93) but not haloperidol or perphenazine. Olanzapine was associated with the highest risk of weight gain (relative risk: 1.44-3.22). Aripiprazole was associated with lower risk of hyperprolactinemia than all the other drugs (relative risks: 0.11-0.21). Ziprasidone and aripiprazole were associated with lower risks of weight gain and metabolic side effects. Haloperidol was associated with a higher risk of extrapyramidal symptoms than all other drugs (relative risks: 0.13-0.61). Aripiprazole was least sedating (relative risks: 0.30-0.39). Olanzapine and risperidone showed lower all-cause discontinuation rates than ziprasidone and haloperidol (hazard ratios: 0.61-0.73). CONCLUSIONS: This trial fills important knowledge gaps in acute antipsychotic treatment of schizophrenia. It confirms hierarchies in efficacy and side effects of antipsychotics from related evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsSchizophreniaHumansAdultMaleFemaleHaloperidolAcute DiseaseMiddle AgedTreatment OutcomePerphenazineOlanzapineRisperidoneThiazolesBenzodiazepinesQuetiapine FumaratePiperazinesYoung AdultAripiprazoleAdolescentPsychiatric Status Rating ScalesQuinolones

Stichwörter der Autor:innen

Acute ExacerbationAntipsychotic DrugsHead-to-Head ComparisonMonotherapyRandomized Controlled TrialSchizophrenia

Substanzen

Antipsychotic AgentsHaloperidolziprasidonePerphenazineOlanzapineRisperidoneThiazolesBenzodiazepinesQuetiapine FumaratePiperazines

Autor:innen und Institutionen

  • Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Ho…
  • Department of Psychiatry and Psychotherapy, TUM School of Medicine and Health, Technical University of Munich, Munich.
  • Clinical Research Institute, Institute of Advanced Clinical Medicine, Peking University, Beijing.
  • Second Xiangya Hospital of Central South University, Changsha, China.
  • Mental Health Center and Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu.
  • Affiliated Mental Health Center and Hangzhou Seventh People's Hospital and School of Brain Science and Brain Medicine, Zhejiang University School of Medicine, Hangzhou.

ORCID-Profile: Yundan Liao, Stefan Leucht

Zitieren

APA

Zhao, G., Sun, Y., Zhang, Y., Lu, T., Lu, Z., Kang, Z., Schneider-Thoma, J., Xie, W., Yang, Y., Guo, J., Zhu, Y., Yuan, R., Sun, J., Feng, X., Liao, Y., Chen, D., Li, L., Li, T., Yang, F., …, & Yue, W. (2026). Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial. American Journal of Psychiatry, 183(2), 112-123. https://doi.org/10.1176/appi.ajp.20250111

Vancouver

Zhao G, Sun Y, Zhang Y, Lu T, Lu Z, Kang Z, et al. Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial. American Journal of Psychiatry. 2026;183(2):112-123. doi:10.1176/appi.ajp.20250111

BibTeX
@article{Zhao2026,
  author = {Zhao, Guorui and Sun, Yaoyao and Zhang, Yuyanan and Lu, Tianlan and Lu, Zhe and Kang, Zhewei and Schneider-Thoma, Johannes and Xie, Wuxiang and Yang, Yang and Guo, Jing and Zhu, Yunqing and Yuan, Rui and Sun, Junyuan and Feng, Xiaoyang and Liao, Yundan and Chen, Dongxue and Li, Lingjiang and Li, Tao and Yang, Fude and Wang, Chuanyue and Zhang, Dai and Yan, Hao and Leucht, Stefan and Yue, Weihua},
  title = {Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial},
  journal = {American Journal of Psychiatry},
  year = {2026},
  volume = {183},
  number = {2},
  pages = {112--123},
  doi = {10.1176/appi.ajp.20250111}
}
Kostenlos starten →